AstraZeneca Pharmaceuticals LP should get a reprieve from the disability bias claim of an employee fired for refusing ...

BNP Paribas Exane initiated coverage of AstraZeneca (AZN) with an Outperform rating and $75 price target Stay Ahead of the Market: Discover ...

AstraZeneca PLC closed 22.92% short of its 52-week high of £133.88, which the company reached on September 3rd.

The AstraZeneca PLC ADR AZN slid 2.83% to $64.87 Thursday, on what proved to be an all-around poor trading session for the ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p14,200.00. The ...

AstraZenca is testing a once-daily PCSK9 inhibitor, currently known as AZD0780. After 12 weeks of use alongside standard ...

AstraZeneca Pharmaceuticals LP and a Christian sales specialist have agreed to settle his suit over the company’s failure to ...

MLB Opening Day 2025 is finally upon us and all eyes will be on the Los Angeles Dodgers after their World Series win in 2024. The Dodgers technically already opened their season with a sweep of ...

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts, while ...

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here are the latest forecasts. When investing, your capital is at risk. The ...

LONDON (Reuters) - AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after ...